93 related articles for article (PubMed ID: 11249776)
1. Technology evaluation: gene therapy (IL-2), Valentis Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):448-52. PubMed ID: 11249776
[TBL] [Abstract][Full Text] [Related]
2. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
3. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer.
Li D; Jiang W; Bishop JS; Ralston R; O'Malley BW
Clin Cancer Res; 1999 Jun; 5(6):1551-6. PubMed ID: 10389944
[TBL] [Abstract][Full Text] [Related]
4. Technology evaluation: VEGF165 gene therapy, Valentis Inc.
Morse MA
Curr Opin Mol Ther; 2001 Feb; 3(1):97-101. PubMed ID: 11249737
[TBL] [Abstract][Full Text] [Related]
5. IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial.
Horton HM; Lalor PA; Rolland AP
Methods Mol Biol; 2008; 423():361-72. PubMed ID: 18370214
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
7. Combination nonviral cytokine gene therapy for head and neck cancer.
Li D; Zeiders JW; Liu S; Guo M; Xu Y; Bishop JS; O'Malley BW
Laryngoscope; 2001 May; 111(5):815-20. PubMed ID: 11368072
[TBL] [Abstract][Full Text] [Related]
8. Liposomal transfection of squamous carcinoma cells of the head and neck with IL-2 and B7 plasmids inducing an autologous immune response in vitro.
Mayer A; Andratschke M; Pauli C; Reitberger E; Kolbow K; Wollenberg B
Anticancer Res; 2005; 25(6B):3917-23. PubMed ID: 16309178
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma.
Figlin RA; Parker SE; Horton HM
Curr Opin Mol Ther; 1999 Apr; 1(2):271-8. PubMed ID: 11715951
[TBL] [Abstract][Full Text] [Related]
10. Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma.
Liu S; Yang H; Liang C
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):323-6. PubMed ID: 12408755
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
12. [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
Yang H; Liu S; Liang C; Peng W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):9-11, 30. PubMed ID: 15600166
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration.
Anwer K; Kao G; Proctor B; Anscombe I; Florack V; Earls R; Wilson E; McCreery T; Unger E; Rolland A; Sullivan SM
Gene Ther; 2000 Nov; 7(21):1833-9. PubMed ID: 11110415
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
Chang CY; Lee J; Kim EY; Park HJ; Kwon CH; Joh JW; Kim SJ
BMC Cancer; 2007 May; 7():87. PubMed ID: 17519043
[TBL] [Abstract][Full Text] [Related]
15. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.
Bray D; Yu SZ; Koprowski H; Rhee J; Kumar S; Pericle F; Suntharalingam M; Van Echo DA; Li D; O'Malley BW
Arch Otolaryngol Head Neck Surg; 2003 Jun; 129(6):618-22. PubMed ID: 12810463
[TBL] [Abstract][Full Text] [Related]
16. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.
Qin H; Valentino J; Manna S; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; O'Malley BW; Chatterjee SK
Mol Ther; 2001 Dec; 4(6):551-8. PubMed ID: 11735339
[TBL] [Abstract][Full Text] [Related]
19. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
[TBL] [Abstract][Full Text] [Related]
20. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation.
Lohr F; Lo DY; Zaharoff DA; Hu K; Zhang X; Li Y; Zhao Y; Dewhirst MW; Yuan F; Li CY
Cancer Res; 2001 Apr; 61(8):3281-4. PubMed ID: 11309280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
